In short
Clinical trials investigating HYDROMORPHONE HYDROCHLORIDE are studying intravenous opioid agonist therapy in people with opioid dependence. This article summarizes what the trial aimed to test, who it enrolled, the phase, and the main outcomes, such as safety, feasibility, and reduced outside opioid use.
Key points
- One completed Phase 2 trial studied HYDROMORPHONE HYDROCHLORIDE as intravenous opioid agonist therapy in people with opioid dependence. The study enrolled 30 participants and looked at whether the treatment could be used safely and feasibly in clinical practice. The main outcome was a reduction in intravenous opioid use outside the medical setting. It also examined whether the offer was accepted by patients and staff, and whether health, social situation, delinquency, and treatment retention improved. The trial focused on real-world use in Vienna and aimed to reach people who had not been well served by existing treatment options.
Trial overview
The trial titled “Pilot study on the safety and feasibility of intravenous opioid agonist therapy (OAT) with Hydagelan® (hydromorphone hydrochloride) in Vienna” studied HYDROMORPHONE HYDROCHLORIDE in a real-world treatment setting. It was completed and enrolled 30 people.
This was an interventional study, which means the research team gave a treatment and then measured the results.
Who was studied
The trial focused on people with opioid dependence, a serious and usually long-lasting condition that affects physical health, mental health, and social life. The study also aimed to include further target groups that had not yet been reached well, or had been reached only poorly, by existing treatment services.
The trial was carried out with the goal of making treatment more accessible for patients who may not have benefited enough from other options.
What was tested
The study tested intravenous opioid agonist therapy (OAT) using Hydagelan® (hydromorphone hydrochloride) in Vienna. “Intravenous” means the medicine was given into a vein.
The trial looked at whether this approach could be built into clinical practice and whether it was safe in this treatment setting. It also checked whether patients and staff at Suchthilfe Vienna gGmbH accepted the offer of this treatment.
Main outcomes and what they mean
The primary outcome was the reduction of intravenous opioid use outside the medical setting. In simple terms, the study wanted to see whether treatment could lower opioid use that happens outside supervised care.
The trial also measured feasibility of implementation and execution, which means whether the treatment could be started and run successfully in practice.
Other goals included checking whether the general state of health, both physical and psychological, became more stable, whether the social situation improved, whether delinquency decreased, and whether more people stayed in treatment.
Study design and phase
This was a Phase 2 trial. Phase 2 studies usually explore whether a treatment may help and continue to watch for safety and practical use.
The study was a pilot project, which means it was a small early study meant to test the idea before larger research.
Why this trial matters
This trial is important because it looked beyond medicine alone and focused on real-life treatment use, patient acceptance, and social outcomes. It aimed to see whether HYDROMORPHONE HYDROCHLORIDE could help reduce unsafe opioid use and support better stability in people with opioid dependence.
Because the study was completed, its results can help explain whether this approach is practical for treatment programs in similar settings.